Highlights

  • FPH shares closed at $37.09, up 2.15% on 24 August 2026
  • FY2026 results remain the company's key recent financial milestone
  • Ongoing global growth and product innovation across respiratory-care products
  • Strategy focused on expanding international presence in hospital and home-care settings

Fisher & Paykel Healthcare Corporation Ltd (ASX:FPH) shares closed at $37.09, up 2.15% on 24 August 2026. The stock continues to draw investor interest given the company's long-running growth trajectory across its respiratory-care and hospital-care product lines, even as it trades at elevated valuation levels relative to the broader healthcare sector.

About Fisher & Paykel Healthcare Corporation Ltd

Fisher & Paykel Healthcare Corporation Ltd is a New Zealand-headquartered medical device company listed on the ASX, specialising in respiratory-care and humidification technologies used across hospital and home-care settings. The company designs and manufactures products for a range of clinical applications, including respiratory support, obstructive sleep apnoea treatment, and surgical humidification, serving both acute hospital environments and long-term home-care patients. Fisher & Paykel Healthcare has built a strong reputation for product innovation, investing heavily in Research and Development to maintain its competitive position within the global respiratory-care device market. Its dual focus on hospital and home-care segments provides Diversification across different care settings and reimbursement environments, while its international footprint spans numerous countries, reducing reliance on any single healthcare market. The company's long track record of consistent innovation and global expansion has made it one of the more highly regarded healthcare technology companies on the ASX, though this quality has also historically been reflected in a premium valuation relative to many industry peers.

Key Developments

Fisher & Paykel Healthcare continues to benefit from Demand for its respiratory-care products, with the company's latest investor information highlighting ongoing global growth and product innovation. Its FY2026 results remain the key recent financial milestone for the business, providing the most comprehensive recent update on trading performance, margins and growth across its various product categories and geographic markets. Alongside these results, management continues investing in new respiratory and hospital-care technologies, reflecting the company's long-standing strategy of prioritising research and development to sustain its innovation pipeline over the long term. The company's strategy is focused on expanding its international market presence and developing products across both hospital and home-care settings, an approach designed to capture demand across the full spectrum of respiratory-care needs. Recent investor attention has centred on improving Earnings momentum, margins and the company's innovation pipeline, all of which are viewed as key indicators of the sustainability of Fisher & Paykel Healthcare's growth story. These factors continue to support expectations for continued long-term growth, despite the elevated valuation levels at which the stock trades, with investors generally willing to pay a premium for the company's track record of consistent execution and innovation.

Conclusion

Fisher & Paykel Healthcare's continued momentum across its respiratory-care and hospital-care product lines reinforces its position as a Long-term Growth story within the ASX healthcare sector. With ongoing Investment in innovation and international expansion, the company appears well placed to sustain its growth trajectory, even as valuation remains a key consideration for investors. Future updates on margins, product adoption and geographic expansion will be important in determining whether the company can continue to justify its premium market rating.